New Product: NXtec D008 DMD – Gold Standard Certainty for CNV Detection in DMD with Enhanced Resolution
We have just launched NXtec D008 DMD – the first dedicated neuromuscular assay to be added to our digitalMLPA™ catalogue – designed for the confident and accurate detection of copy number variations (CNVs) in the DMD gene and its flanking regions, and for the detection of X-chromosome aneuploidies.
What makes NXtec D008 DMD stand out?
NXtec D008 DMD delivers highly reliable detection of CNVs associated with Duchenne and Becker muscular dystrophies. This NGS-based assay provides comprehensive coverage of DMD with two probes per each of its 79 exons, and 50 additional probes distributed across the X chromosome to aid with result interpretation. With a robust performance on various sample types*, NXtec D008 DMD is a high-throughput assay that can cover a variety of analytical needs.
Introductory offer
To celebrate the launch of NXtec D008 DMD, we are offering a 40% discount to first-time digitalMLPA users on a digitalMLPA start-up package including all necessary digitalMLPA reagents, valid until December 31st, 2026 (conditions apply).
Existing digitalMLPA users are also eligible for a 50% discount on the D008 DMD probemix itself!
Receive your personal quote today
Key features
-
Targeted assay – detection of single-exon to whole-gene CNVs in DMD, as well as larger X-chromosome CNVs and aneuploidies in a single reaction.
-
Easy integration into existing NGS workflows.
-
Minimal DNA input requirements (as low as 20 ng).
-
Quick turnaround – from DNA sample to sequencer in <24 hours.
-
Competitive pricing – <€30 EUR per sample** (comparable to two conventional MLPA reactions).
-
Free, easy-to-use analysis software – no bioinformatics expertise needed.
MRC Holland's genetic testing solutions for DMD
NXtec D008 DMD is the latest addition to our portfolio of assays that detect CNVs related to Duchenne and Becker muscular dystrophies, which further consists of the gold standard, IVDR-certified MLPA probemixes P034 DMD Mix 1 & P035 DMD Mix 2, and the broader digitalMLPA panel for carrier status analysis of ten disorders, NXtec D028 Carrier Panel 1.
* Tested on peripheral blood samples with and without CNVs in DMD, and on amniotic fluid (23-30 weeks) and CVS samples (12-19 weeks) without CNVs in DMD.
** Costs based on list prices and do not include sequencing reagents. Prices may differ when ordering through our sales partners.